MedTrace Logo

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

NCT04543110 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-03-23

No results posted yet for this study

Summary

This study assesses the effect of sequential radiation and durvalumab immunotherapy given as treatment prior to surgery with radical cystectomy for bladder cancer.

Conditions

Interventions

DRUG

Durvalumab

Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma

RADIATION

Immune Modulating Radiation

Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma

Sponsors & Collaborators

  • Cross Cancer Institute

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • London Health Sciences Centre

    collaborator OTHER

  • Ontario Institute for Cancer Research

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Ozmosis Research Inc.

    collaborator INDUSTRY

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Michael Ong, MD · Ottawa Hospital Research Institute

  • Naveen Basappa, MD · Cross Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-29
Primary Completion
2023-10-31
Completion
2024-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04543110 on ClinicalTrials.gov